Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...

Use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) may be linked with an increased risk of the second most common form of optic neuropathy, a retrospective study suggested. Over a mean ...

Patients who took the frequently prescribed diabetes and weight-loss drugs Ozempic and Wegovy faced a greater risk of a stroke of the optic nerve, which can lead to blindness, according to a new study ...

GLP-1 medications have been linked to a scary side effect that involves vision loss. So far, there have been a few studies tying NAION to semaglutide. Here's what doctors say about the rare side ...

People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn’t deter patients from using the medicines to treat ...

People taking Ozempic and Wegovy may be at increased risk of developing a debilitating eye condition that can cause irreversible vision loss, a study published Wednesday in JAMA Ophthalmology finds.

Authors of a new study say additional research is needed to determine causality between semaglutide and a condition called NAION Mario Tama/Getty People who take Ozempic and Wegovy may have a higher ...

Maggie O’Neill is a health writer and reporter based in New York who specializes in covering medical research and emerging wellness trends, with a focus on cancer and addiction. Prior to her time at ...

In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, amid alarming reports of a possible connection to a serious eye condition ...

Recent studies have highlighted some of the most common side effects related to Ozempic and other weight loss drugs, including digestive issues and even dehydration. Now, a new study conducted by ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes or obesity using a GLP-1 had a similar risk for NAION as those using non-GLP-1 drugs ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for type 2 diabetes and weight loss. Medications such as Ozempic, Wegovy, Mounjaro ...